Showing results (601-610 of 3,353) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|June 30, 2022
2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19Dominique Farge, Corinne Frere, Jean M Connors, et al.
The Lancet. Oncology|May 28, 2021
Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based studyRafael Cardoso, Feng Guo, Thomas Heisser, et al.
The Lancet. Oncology|May 30, 2021
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trialPeter R Galle, Richard S Finn, Shukui Qin, et al.
The Lancet. Oncology|July 3, 2021
The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology researchPriya Ranganathan, Girish Chinnaswamy, Manju Sengar, et al.
The Lancet. Oncology|September 13, 2020
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 studyAurélien Marabelle, Marwan Fakih, Juanita Lopez, et al.
The Lancet. Oncology|September 13, 2020
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trialNicholas C Turner, Belinda Kingston, Lucy S Kilburn, et al.
The Lancet. Oncology|September 14, 2020
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 studyKarim Fizazi, Gero Kramer, Jean-Christophe Eymard, et al.
The Lancet. Oncology|September 23, 2020
Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 studyJianming Xu, Lin Shen, Chunmei Bai, et al.
The Lancet. Oncology|September 23, 2020
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 studyJianming Xu, Lin Shen, Zhiwei Zhou, et al.
The Lancet. Oncology|April 3, 2020
Sustainable care for children with cancer: a Lancet Oncology CommissionRifat Atun, Nickhill Bhakta, Avram Denburg, et al.
Pageof 336